B2i Digital Featured Company_AIM ImmunoTech Inc_NYSE AIM_Logo

AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is an immuno-pharma company primarily engaged in developing therapeutics for various significant diseases, including multiple types of cancers, immune disorders, and viral infections like COVID-19. The company's flagship product, Ampligen® (rintatolimod), is an immune-modulator under development for various indications. It's notable for its broad-spectrum activity and is currently involved in numerous clinical studies aimed at demonstrating its efficacy across multiple high-value disease areas, including oncology and chronic viral diseases.

NYSEAMERICAN: AIM
IR Website:
aimimmuno.com

Headquarters: Ocala, FL

Investor Contact: aim@jtcir.com

FB-logo-white   x-logo   linkedin-logo-white

TALK TO MANAGEMENT

AIM ImmunoTech Inc.  is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Summary

Press Releases

Social Media Updates

Investor Presentation

Stock Chart (Intraday)

Stock Chart (Historical)

Stock Detail

CEO Corner Videos & Virtual Investor Series

Ampligen® - A Wide Variety of Potential Applications

Ampligen® - Mechanism in Oncology

Ampligen® - In Oncology Programs

Ampligen® - In Pancreatic Cancer Programs

Ampligen® - As a Potential Treatment for Post-COVID Conditions: Fatigue

Market Potential

Ampligen® Current Pipeline

Alferon N Injection®

Strong Cash Position & Poised for Commercialization

SEC Filings

Management Overview

Risks & Disclosures

AIM Logo White

The AIM ImmunoTech's management and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

• Directly hear the AIM ImmunoTech story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible

Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.